Recent investigations on retatrutides, a dual activator for glucagon-like peptide-1 and GIP, indicate significant outcomes in treating weight gain and type 2 diabetes. Preliminary evidence from clinical trials show substantial reductions in body mass and bettered glucose regulation. Additional re